Novo Nordisk A/S (NVO)

123.05 -0.97 (-0.78%) 收市：04:00PM EDT

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

版塊: Healthcare
行業: Biotechnology
全職員工: 63,370

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Lars Fruergaard Jorgensen	President, CEO & Member of Management Board	4.62M	無	1966
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board	1.83M	無	1971
Mr. Henrik Ehlers Wulff	Executive VP of Product Supply, Quality & IT and Member of the Management Board	1.84M	無	1970
Ms. Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	1.8M	無	1972
Dr. Martin Holst Lange	Executive VP of Development & Member of the Management Board	1.74M	無	1970
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board	1.74M	無	1966
Mr. Maziar Mike Doustdar	Executive VP of International Operations & Member of the Management Board	無	無	1970
Mr. Douglas J. Langa	Executive VP of North America Operations & Member of Management Board	無	無	1966
Mr. Ludovic Helfgott	Executive VP, Head of Rare Disease & Member of Management Board	無	無	1974
Ms. Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	無	無	1977

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

公司管治

截至 2024年5月1日 止，Novo Nordisk A/S 的 ISS 管治質素評分為 1。 Pillar 分數正在審核中：3；董事會：2；股東權利：9；現金賠償：1。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。